Evidence map›Paper›PMID 34439833›Full record

ReviewBiomolecules2021

The Role of Galectin-3 and ST2 in Cardiology: A Short Review.

Ana Merino-Merino, Jeronimo Gonzalez-Bernal, Dario Fernandez-Zoppino, Ruth Saez-Maleta, Jose-Angel Perez-Rivera

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. NSTEMI Risk Prediction with the Combination of the Biomarkers Epicardial Adipose Tissue and Soluble Suppression of Tumorigenicity 2.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Observational
  12. Is soluble ST2 an useful biomarker for early diagnosis of coronary atherosclerosis?Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Review
  19. Cytotoxic CD8Cells · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Ana Merino-MerinoDepartment of Cardiology, University Hospital of Burgos, 09005 Burgos, Spain.ORCID 0000-0001-9563-5305
Jeronimo Gonzalez-BernalDepartment of Health Sciences, University of Burgos, 09005 Burgos, Spain.ORCID 0000-0002-7298-9060
Dario Fernandez-ZoppinoDepartment of Health Sciences, University of Burgos, 09005 Burgos, Spain.ORCID 0000-0002-9763-7328
Ruth Saez-MaletaDepartment Clinical Analysis, University Hospital of Burgos, 09005 Burgos, Spain.
Jose-Angel Perez-RiveraDepartment of Cardiology, University Hospital of Burgos, 09005 Burgos, Spain.ORCID 0000-0003-1451-1445
Universidad de Burgos · ESCentro Científico Tecnológico - San Juan · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Galectin-3 is a lectin that binds beta-galactosides. It is involved in cardiac remodeling and fibrosis through the activation of macrophages and fibroblasts. ST2 is secreted by myocardial cells due to cardiac overload. These two biomarkers have been traditionally studied in the field of heart failure to guide medical therapy and detect the progression of the disease. Nevertheless, there are novel evidences that connect galectin-3 and ST2 with coronary heart disease and, specifically, with atrial fibrillation. The aim of this article is to concisely review the diagnostic and prognostic role of galectin-3 and ST2 in different cardiac diseases.

Indexed as

Atrial FibrillationBiomarkersBlood ProteinsCoronary DiseaseDisease ProgressionFibroblastsGalectinsHeartHeart FailureHumansInterleukin-1 Receptor-Like 1 ProteinMacrophagesMyocardial IschemiaNatriuretic Peptide, BrainPeptide FragmentsPrognosisBiomarkersBlood ProteinsGalectinsIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 ProteinLGALS3 protein, humanNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Troponinbiomarkerscardiologygalectin-3ST2

Identifiers

PMID34439833
PMCPMC8393977
OpenAlexW3189836466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.